Skip to main content

Immuno-Biological Laboratories Co., Ltd.

株式会社免疫生物研究所

Valuation

Fundamental ratios for the latest reported period.

Ticker: 4570
FY2025 · 2026-03-31
Gross margin70.4%
Operating margin28.0%
Net margin32.7%
Return on equity17.8%
Return on assets15.3%
Revenue growth (YoY)3.7%
EPS (basic)¥35.33
EPS growth (YoY)32.1%
Current ratio5.68x
Equity ratio85.5%
Book value / share¥197.93
Free cash flow268 M